家族性腺瘤性息肉病 中国就医指南

Familial Adenomatous Polyposis (FAP) is a rare, autosomal dominant inherited disorder characterized by the development of hundreds to thousands of colorectal adenomatous polyps, typically beginning in adolescence. Left untreated, these polyps carry an almost 100% lifetime risk of progressing to colorectal cancer—usually by age 40–50. FAP results from germline pathogenic variants in the APC (adenomatous polyposis coli) gene on chromosome 5q21–22, which encodes a tumor suppressor protein critical for regulating β-catenin degradation, cell adhesion, migration, and apoptosis. Loss of functional APC leads to constitutive WNT pathway activation, uncontrolled epithelial proliferation, and rapid adenoma formation throughout the colorectum. A milder variant, attenuated FAP (AFAP), presents with fewer polyps (typically 10–100), later onset (mean age ~55), and lower—but still significantly elevated—cancer risk. Epidemiologically, FAP affects approximately 1 in 7,000 to 1 in 22,000 individuals worldwide, with no ethnic or gender predilection; about 25–30% of cases arise from de novo mutations, meaning affected individuals may be the first in their family with the condition. Key risk factors include having a first-degree relative with FAP (conferring 50% inheritance risk) and confirmed APC mutation status. Extracolonic manifestations are common and clinically significant: duodenal and periampullary adenomas (present in up to 90% of adults with FAP, with 3–5% lifetime risk of duodenal cancer), gastric fundic gland polyps, osteomas, dental anomalies, congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors (occurring in 10–20%, often post-surgery and potentially life-threatening due to local invasion), and increased risks of thyroid (especially papillary), brain (medulloblastoma in Turcot syndrome variant), and hepatoblastoma (in young children). Quality of life is profoundly impacted—not only by the psychological burden of lifelong surveillance, high cancer anxiety, and prophylactic surgery decisions, but also by physical consequences: colectomy often necessitates ileorectal anastomosis (IRA) or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA), both associated with bowel frequency, urgency, nocturnal seepage, sexual dysfunction, and infertility concerns (particularly in women after IPAA or desmoid-related pelvic surgery). Desmoid disease can cause chronic pain, organ compression, and functional impairment. Genetic counseling, early endoscopic screening starting at age 10–12, and timely surgical intervention remain cornerstones of management. With comprehensive care—including genetic testing, coordinated gastroenterology, surgical oncology, and psychosocial support—life expectancy approaches normal, though lifelong multidisciplinary follow-up is essential.

# 家族性腺瘤性息肉病（FAP）治疗方案与费用明细（消化内科）

一、非手术/保守管理方案

适用于：基因确诊但尚未出现≥10枚结直肠腺瘤、无高危病理特征者；或无法耐受手术的高龄/合并严重基础病患者。

• •内镜监测+药物干预：每6–12个月高清结肠镜（含染色放大），每次检查费 1,800–3,200元；
• •化学预防：塞来昔布（200 mg bid）或舒林酸，年药费 4,500–9,800元（医保乙类，自付约30%–50%）；
• •必查项目：*APC*基因检测（首次）3,500元，上消化道内镜（胃/十二指肠）1,200–2,000元，腹部超声/CT（年度筛查）600–1,500元。

二、手术/根治性方案

适用于：结直肠腺瘤≥20枚、存在高级别异型增生、或已进展为癌者。

• •腹腔镜全结直肠切除+回肠储袋肛管吻合术（IPAA）：

- 术前全套检查（肠镜+病理+心肺功能+基因确认）5,200–7,600元；

• •全结直肠切除+回肠造口术（Hartmann术式）：适用于高龄/盆腔粘连/肛门功能差者，费用 52,000–73,000元。

三、特殊复杂情况处理

• •合并十二指肠乳头腺瘤（Spigelman IV级）：内镜下乳头切除（ERCP+EST）12,000–22,000元/次；
• •FAP相关胃癌/胰腺癌晚期：姑息化疗（FOLFOX方案）单周期 18,000–26,000元（含基因检测及支持治疗）。

四、方案快速选择指南

✅ 预算有限/早期无症状者：首选内镜监测+塞来昔布（年均支出≤1.5万元）； ✅ 中青年确诊者（<40岁）：强烈推荐IPAA根治术（医保报销后自付约2.5–4万元）； ✅ 高龄/多系统衰竭者：保守监测+个体化减瘤内镜，避免手术风险。